多组学与人工智能融合驱动精准药物研发中的应用进展
许成1 蒋海兵1 黄宇1 黄思婷1 王栋昌1 何秋婷1 黄璐2（通讯作者） 张涛1（通讯作者）

1重庆科技大学，重庆市沙坪坝区，401331；

2重庆邮电大学，重庆市南岸区，400065；

摘要：全球新药研发的临床转化效率仍有待提高，传统“一药一靶”策略难以应对复杂疾病的多层次病理机制。多组学技术与人工智能（artificial intelligence，AI）的发展，推动药物研发由经验驱动逐渐转向数据驱动和智能辅助。本文综述多组学与AI融合技术在靶点发现、药物重定位、候选分子设计及临床试验优化中的应用进展，重点阐述多组学数据在疾病网络解析、药物响应预测中的作用，以及AI模型在分子生成、安全性评价和临床决策支持中的应用。现阶段，数据异质性、模型可解释性不足以及人群代表性有限仍制约相关技术的临床转化。未来，联合学习、类器官与器官芯片验证体系以及FAIR数据原则的进一步发展，有望促进精准药物研发模式的持续优化。

关键词：多组学；人工智能；药物研发；精准医学；药物重定位；临床试验

参考文献

[1]Minikel E V,Painter J L,Dong C C,et al.Refining the impact of genetic evidence on clinical success. Nature.2024,629(8012):624-629.

[2]Ghosh S,Zhao X,Alim M,et al.Artificial intelligence applied to ’omics data in liver disease:towards a personalised approach for diagnosis,prognosis and treatment.Gut.2025,74(2):295-311.

[3]He X, Liu X, Zuo F, et al. Artificial intelligence-based multi-omics analysis fuels cancer precision medicine. Seminars in Cancer Biology. 2023, 88: 187-200.

[4]Cui H, Wang C, Maan H, et al. scGPT: toward building a foundation model for single-cell multi-omics using generative AI. Nature Methods. 2024, 21(8): 1470-1480.

[5]Pacini C,Duncan E,Gonçalves E,et al.A comprehensive clinically informed map of dependencies in cancer cells and framework for target prioritization.Cancer Cell.2024,42(2):301-316.e9.

[6]Qin Y, Liu Y, Xiang X, et al. Cuproptosis correlates with immunosuppressive tumor microenvironment based on pan-cancer multiomics and single-cell sequencing analysis. Molecular Cancer.2023,22(1):59.

[7]Zhou S,Zhang H,LI J,et al.Potential anti-liver cancer targets and mechanisms of kaempferitrin based on network pharmacology,molecular docking and experimental verification. Computers in Biology and Medicine.2024,178:108693.

[8]Albuquerque A M, Eckert I, Tramujas L, et al. Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis. Clinical Microbiology and Infection.2023,29(1):13-21.

[9]Yuan Z,Wang J,Qu Q,et al. Celastrol combats methicillin-resistant staphylococcus aureus by targeting Δ1-pyrroline-5-carboxylate dehydrogenase.Advanced Science.2023,10(25):2302459.

[10]Gold E R, Cook-Deegan R.AI drug development’s data problem. Science.2025,388(6743):131.

[11]Ren F,Aliper A,Chen J,et al.A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nature Biotechnology.2025,43(1):63-75.

[12]Lin X,Dai L, Zhou Y, et al. Comprehensive evaluation of deep and graph learning on drug–drug interactions prediction. Briefings in Bioinformatics. 2023, 24(4): bbad235.

[13] Nyamabo A K, Yu H, Shi J Y. SSI-DDI: substructure-substructure interactions for drug-drug interaction prediction. Briefings in Bioinformatics. 2021, 22(6): bbab133.

[14]Järvinen E,Hammer H S, Pötz O, et al. 3D spheroid primary human hepatocytes for prediction of cytochrome P450 and drug transporter induction. Clinical Pharmacology and Therapeutics. 2023, 113(6): 1284-1294.

[15]Smith G F.Artificial intelligence in drug safety and metabolism. Methods in Molecular Biology. 2022, 2390: 483-501.

[16]Joshi P,V M,Mukherjee A.A knowledge graph embedding based approach to predict the adverse drug reactions using a deep neural network.Journal of Biomedical Informatics.2022,132:104122.

[17]Limeta A,Gatto F,Herrgård M J,et al.Leveraging high-resolution omics data for predicting responses and adverse events to immune checkpoint inhibitors. Computational and Structural Biotechnology Journal.2023,21:3912-3919.

[18]Kan Z,Wen J, Bonato V, et al. Real-world clinical multi-omics analyses reveal bifurcation of ER-independent and ER-dependent drug resistance to CDK4/6 inhibitors. Nature Communications. 2025, 16(1): 932.

[19]Imai M, Nakamura Y, Shin S, et al. Artificial intelligence-powered human epidermal growth factor receptor 2 and tumor microenvironment analysis in human epidermal growth factor receptor 2-amplified metastatic colorectal cancer: exploratory analysis of phase II TRIUMPH trial. JCO precision oncology. 2025, 9: e2400385.

[20]Li J, Li L, You P, et al. Towards artificial intelligence to multi-omics characterization of tumor heterogeneity in esophageal cancer. Seminars in Cancer Biology, 2023, 91: 35-49.

[21]Sinha S, Vegesna R, Mukherjee S, et al. PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors. Nature cancer. 2024, 5(6): 938-952.

[22]Harrer S, Shah P, Antony B, et al. Artificial intelligence for clinical trial design. Trends in Pharmacological Sciences. 2019, 40(8): 577-591.

[23]Fountzilas E,Tsimberidou A M,Vo H H,et al. Clinical trial design in the era of precision medicine.Genome Medicine.2022,14(1):101.

[24]Rodriguez S, Hug C, Todorov P, et al. Machine learning identifies candidates for drug repurposing in alzheimer’s disease. Nature Communications. 2021, 12(1): 1033.

[25]Giudice V, Biancotto A, Wu Z, et al. Aptamer-based proteomics of serum and plasma in acquired aplastic anemia. Experimental Hematology. 2018, 68: 38-50.

[26]Saettini F, Guerra F, Mauri M, et al. Biallelic PI4KA mutations disrupt B-cell metabolism and cause B-cell lymphopenia and hypogammaglobulinemia. Journal of Clinical Immunology. 2024,45(1): 15.

[27]Jusoh A S,Remli M A,Mohamad M S,et al.How generative artificial intelligence can transform drug discovery?.European Journal of Medicinal Chemistry.2025,295:117825.

[28]Cyranoski D.AI drug discovery booms in China.Nature Biotechnology.2021,39(8):900-902.

[29]Wang Y, Yang Z, Yao Q. Accurate and interpretable drug-drug interaction prediction enabled by knowledge subgraph learning. Communications Medicine. 2024, 4(1): 59.

[30]Cao P Y,He Y,Cui M Y,et al.Group graph:a molecular graph representation with enhanced performance, efficiency and interpretability.Journal of Cheminformatics.2024,16(1):133.

[31]Park Y, Hu J, Singh M, et al. Comparison of methods to reduce bias from clinical prediction models of postpartum depression. JAMA network open. 2021, 4(4): e213909.

[32]Zhou W, Kanai M, Wu K H H, et al. Global biobank meta-analysis initiative: powering genetic discovery across human disease. Cell Genomics. 2022, 2(10): 100192.

[33]Xu Z, Lee D S, Chandran S, et al. Structural variants drive context-dependent oncogene activation in cancer. Nature. 2022, 612(7940): 564-572.

[34]Ren F, Aliper A, Chen J, et al. A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nature Biotechnology.2025,43(1):63-75.